SAN FRANCISCO–(BUSINESS WIRE)–InterVenn Biosciences, the leader in glycoproteomics, today announced Aldo Carrascoso, the company’s CEO and Co-Founder, is scheduled to present at the J.P. Morgan 40th Annual Healthcare Conference on January 12, 2022, from 3:00 – 3:25 pm EST. Mr. Carrascoso will provide a company overview of InterVenn and its first-of-its-kind glycoproteomics solutions.
Following the company presentation, management will participate in a virtual breakout session. InterVenn management will also participate in one-on-one meetings with investors, analysts, and other interested parties during the conference.
Contact
Anthony Petrucci
Bioscribe
anthony@bioscribe.com
2 Tower Place, 5th Floor,
South San Francisco, CA 94080
Bay Area Lab
